EHA 2019 – presentations and articles
During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated interim...
Presentations
ASCO 2019 – presentations and articles
During 2019 ASCO General Meeting (American Society of Clinical Oncology), Oncopeptides presented new data from phase 1/2 O-12-M1 trial evaluating melflufen in RRMM. These data was presented by Professor...
Post EHA – webcast regarding data update
Oncopeptides hosted a webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology Association (EHA) meeting. It was presented by CEO Jakob Lindberg and members...
EHA 2019 – Oral Presentation
Professor Paul G. Richardson held an oral presentation of the study HORIZON at EHA 2019 on 16 June.
REDEYE Growth Day – Presentation
Oncopeptides CFO Anders Martin-Löf held a presentation at the REDEYE Growth Day, 10 June 2019. The Presentation was recorded and can be showed at the link below. Below is also a link to an EFN interview ...
Jefferies 2019 Healthcare Conference, New York – Presentation
Oncopeptides CEO Jakob Lindberg gave a presentation at Jefferies Healthcare Conference in New York June 7, at 17.30 CET. The presentation was webcasted, see link below. You can also listen to the presentation,...
2019 ASCO Annual Meeting – poster
New data from Oncopeptides phase 1/2 O-12-M1 trial evaluating melflufen in RRMM presented at 2019 ASCO annual meeting by Professor Paul G. Richardson.
REDEYE Pre-ASCO Seminar – presentation
CEO Jakob Lindberg presented at the REDEYE Pre-ASCO Seminar, Tuesday May 28, in Stockholm, Sweden. See link to the recording of the presentation below.
Oncopeptides hosting a symposium at the upcoming EHA, 13 June 2019
Oncopeptides hosts a symposium at the upcoming EHA 2019. The symposium takes place on Thursday 13 June, 2019. See the invitation below, welcome to join us.
Webcast regarding operational update
Oncopeptides held an operational update on Tuesday, May 21, 2019, at. 10:00 (CET). It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team. The webcast was recorded. See...
EHA Abstracts 2019
Upcoming presentations at EHA The HORIZON data will be presented as an oral presentation by Professor Paul G. Richardson, in the session “Novel strategies in multiple myeloma” on June 16 at 08.45 (CET) in ...
ASCO Abstract 2019
Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The study e...
Webcast regarding clinical program update
Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The webcast was recorded. See the...
Kempen Life Science Conference 2019 – presentation
Oncopeptides presented at the Kempen Life Science Conference 2019 in Amsterdam, Netherlands.
AACR 2019 – Posters
At the AACR (American Association for Cancer Research) Annual Meeting 2019 Oncopeptides presented two Posters for the studies ANCHOR and HORIZON. AACR Annual Meeting 2019, March 29 - Apr 3, in Atlanta,...
Cowen & Company 39th Annual Health Care Conference – Presentation
CEO Jakob Lindberg presented at Cowen and Company 39th Annual Health Care Conference on March 11, 2019. The presentation was webbcasted, see link below.
Carnegie Healthcare Conference 2019 – presentation
CEO Jakob Lindberg presented at Carnegie Healthcare Conference, on March 6 2019.
Webcast Year-End Report 2018
The Year-end Report for 2018 and an operational update was presented by CEO Jakob Lindberg and members of Oncopeptides management team, February 22, 2019 at 14:00 (CET). The conference was streamed via...
Oncopeptides Capital Markets Day in New York – presentations
Oncopeptides did host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York, here is the presentation from the whole day. Speakers were Jakob Lindberg, Chief Executive Officer, other...
DNB Nordic Healthcare Conference 2018 – presentation
December 12, CEO Jacob Lindberg held a presentation at the DNB Nordic Healthcare Conference 2018 in Oslo.
ASH 2018 – presentations and articles
During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON. These presentations as well as publications in the media are presented below. The...
Jakob Lindberg, CEO, Oncopeptides – Company presentation post ASH
Jakob Lindberg, CEO, Oncopeptides - Company presentation post ASH 2018
Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study
Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study
60th ASH Annual Meeting & Exposition – Poster ANCHOR
ANCHOR poster. Oncopeptides presents the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA (December 1, 2018).
Jefferies 2018 London Healthcare conference – Presentation & webcast
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded. Click on the recording (mp3-file) to view...
ASH Abstracs 2018
Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th....
Lunch presentation at DNB
Corporate presentation by Jakob Lindberg, CEO, Oncopeptides AB, at DNB 25 September 2018.
Presentation at 23rd Congress of The European Hematology Association (EHA)
The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients ...
Jefferies Health Care conference, New York – Presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies Healthcare Conference in New York June 7.
Jakob Lindberg, CEO, is interviewed in Di tv
Oncopeptides CEO Jakob Lindberg interviewed at DI Börsmorgon (Di tv) about the Q1 Interim report and the future, May 17, 2018.
Carnegie Healthcare Seminar 2018 – presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Carnegie Healthcare Seminar on March 14.
SCF Life Science Seminarium – presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Stockholm Corporate Finance Live Science Seminarium March 7. Click here to view the recorded presentation.
ABGSC Orphan Drug Day 2018 – Presentation
Oncopeptides presentation at the ABG Office in Stockholm, Sweden
DNB Nordic Healthcare Conference 2017 – Oslo
Oncopeptides' presentation at DNB in Oslo, 14 December
ASH summary Webcast
Oncopeptides had a press conference on December 13. The conference was recorded. Click here to view the Webcast.
59th ASH Annual Meeting & Exposition – Posters
Horizon Poster (9 Dec 2017) and O-12-M1 Poster (10 Dec 2017)
Carnegie Healthcare Day in New York – presentation
Oncopeptides presentation at Carnegie, New York, 5 December 2017.